JP Morgan On Omnicare After Healthcare Conference

JP Morgan has published a research report on Omnicare, Inc. OCR after the company presented last week at JP Morgan's Healthcare conference. In the report, JP Morgan writes "Brand to generic conversions and productivity improvements are expected to be a positive impact in 1H11 and 2H11, while pricing adjustments and the annualization of bed losses will both be negative factors in 1H, but neutral to 2H, and payroll costs (reinvestment into the business) will be a negative in both periods. Although management pointed to an equal number of positive and negative factors over the course of the year, it did not discuss the relative magnitude of each factor. OCR will provide initial 2011 guidance with 4Q10 results." JP Morgan maintains its Overweight rating and $32 price target. Omnicare, Inc. closed Friday at $26.00.